BetterLife Pharma Inc.
BETR
CNSX
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -55.55% | -45.91% | -38.04% | 60.40% | 79.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -59.71% | -52.75% | -39.47% | 44.87% | 51.21% |
| Operating Income | 59.71% | 52.75% | 39.47% | -44.87% | -51.21% |
| Income Before Tax | 48.09% | 82.04% | 56.89% | -22.48% | -26.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 48.09% | 82.04% | 56.89% | -22.48% | -26.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 108.51% | 98.85% | 98.68% | 1,219.64% | -195.07% |
| Net Income | 56.11% | 83.70% | 61.39% | -19.36% | -82.50% |
| EBIT | 59.71% | 52.75% | 39.47% | -44.87% | -51.21% |
| EBITDA | -- | -- | -- | -- | 76.95% |
| EPS Basic | 63.98% | 86.69% | 64.26% | -11.86% | -61.11% |
| Normalized Basic EPS | 68.51% | 75.00% | 57.26% | -25.87% | -155.43% |
| EPS Diluted | 56.09% | 80.19% | 58.36% | 0.00% | -26.64% |
| Normalized Diluted EPS | 68.51% | 75.00% | 57.26% | -25.87% | -155.43% |
| Average Basic Shares Outstanding | 16.75% | 16.10% | 12.52% | 13.36% | 16.79% |
| Average Diluted Shares Outstanding | 12.69% | 19.83% | 16.34% | 17.32% | 20.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |